back to overview


New MTIP investment in Quanta Dialysis Technologies

June 20, 2018 + Jessica Di Palo
5 Min read

MTIP has invested in Quanta Dialysis Technologies Ltd., a British company that has developed advanced haemodialysis systems for use in clinics and at home.

Quanta haemodialysis solution

MTIP has invested in Quanta Dialysis Technologies Ltd (Quanta), a British company providing innovative haemodialysis solutions for use in clinics and at home.

Renal failure is a huge clinical problem with over two million patients receiving dialysis on a weekly basis. For these patients, treatment consumes great amounts of their time and can be a real burden on their quality of life. Quanta aims to improve these patients’ lives by simplifying and creating more treatment flexibility while maitaining high treatment quality.

“We are delighted to welcome MTIP as an investor and we are grateful for their support at this critical time as we prepare for market launch”, said John E. Milad, CEO of Quanta.

“Quanta has done an amazing job at creating a technology that directly meets the needs of dialysis patient’s. With Quanta‘s SC+ personal haemodialysis, patients will have a simpler and easier treatment whether that be in their local clinic or at home”, said Dr. Christoph Kausch, Founding Partner and CEO of MTIP.

Bruce Meadows, the MTIP’s Senior Investment Director, added that “Quanta is exactly the type of company in our investment sweet spot. It improves patient’s quality of life, it saves them time and it saves money across the healthcare system.”

Share the Article


SFDR Art. 8 or Art. 9? What’s the difference?

SFDR: getting the terminology right


MTIP participates in Oviva’s new $80m Series C funding

Oviva raises $80 million financing round


MTIP invests in Intelligencia to reduce the risk of clinical research through artificial intelligence

MTIP's new investment in Intelligencia


Private Equity 101: Part one – Glossary

Are you new to the healthtech space?


Leading brands revolutionize care journeys with Lumeon

How Lumeon orchestrates care journey


Trialbee – our hero in patient matching and recruiting for clinical trials

Trialbee - patient matching and recruiting

news blog

Digital healthcare: patient-first?

Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital

SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?

New SFDR obligations


MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation

First Closing of Fund II


How to pitch to a healthtech Investor

Blog Pitching


MTIP invests in Koa Health to make mental health treatment more accessible

New investment in Koa Health


MTIP scored fantastic grades in the UNPRI assessment report of 2020

UNPRI Report grades 2020


4 Health VCs Share Their Business Priorities and What is Next

Interview Techtour


MTIP invests in Trialbee

New investment in Trialbee


TytoCare closes $50 million round as the demand for telehealth accelerates

TytoCare closes new round


The digital healthtech sector is expanding – and so are we!

Two new empolyees start in April


MTIP has sucessfully exited Blueprint Genetics

Blueprint exit January 2020


New MTIP investment in Oviva

New investment in Oviva


Whitepaper: A positive prognosis for the future of healthtech

Our first Whitepaper


Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch

Elite Summit 2019


MTIP Healthcare Clinic 2019

Healthcare clinic 2019

New MTIP investment in Cynerio

New investment in Cynerio


MTIP invests in Lumeon Ltd.

New investment in Lumeon

Magenverkleinerung mit der Handnähmaschine

Nitinotes news paper article


New MTIP investment in Quanta Dialysis Technologies

New investment in Quanta